SecBot SecBot

MLTX

MoonLake Immunotherapeutics
Nasdaq· Pharmaceutical Preparations· Inc. E9· CIK 0001821586 Biotech & Drug Discovery
$11.85 −0.49 (−3.97%)
Oct 23 4:00 PM ET · prev $12.34
Market cap
$1.1B
Small cap
Consensus
Buy
77% Buy or better · 22 analysts
Median target
🔒 Subscribers only
1 year
+24.5%
from $9.52 · Oct 24
30 days
−2.2%
from $12.12
52-week range
$9.52–22.16
−47% from high · low Oct 24
Avg volume 20D
1.98M
Oct 22 spike 6.12M
Short interest
8.05M
≈9.5% of shares · −10.1%
Days to cover
4.2
at average volume
Insider net
-$77.0M
0 buyers · 4 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 3 bullish oldest → newest, height = score
Avg score ·High conf. 2/3 ·Next Earnings date, Nov 17, 2026
Strongest BULLISH MoonLake announced positive topline Phase 3 IZAR-1 results for sonelokimab in psoriatic arthritis, meeting…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $77.0M.

  • InstitutionsBULLISH

    Q2 2026: 32 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    17 of 22 rate it Buy or better.

  • Short sellersSTEADY

    Short interest −10.1% to 8.05M shares. 4.2 days to cover, ≈9.5% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
D. E. Shaw & Co., Inc.ADD3,365,507$65.5M
CITADEL ADVISORS LLCADD1,972,893$38.4M
JPMORGAN CHASE & COADD1,386,422$27.6M
JANE STREET GROUP, LLCADD853,386$16.6M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPDOUBLED750,777$14.6M
HRT FINANCIAL LPADD679,244$13.2M
RENAISSANCE TECHNOLOGIES LLCDOUBLED643,268$12.5M
MARSHALL WACE, LLPDOUBLED550,351$10.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

22 analysts
Buy 77% rate it Buy or better
Strong Buy7Buy10Hold3Sell1Strong Sell1

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Oct 5, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 13, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 20, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jul 1, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Jun 9, 2026BTIG
REITERATE
REITERATEBuy
Jun 8, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$77.0M
sold · 4 insiders
DateInsiderTypeValue
Jul 27, 2026
Reich Kristian
Chief Scientific Officer
SELL$22.0K
Jul 22, 2026
Reich Kristian
Chief Scientific Officer
SELL$49.0K
Jul 21, 2026
Reich Kristian
Chief Scientific Officer
SELL$1.0M
Jul 20, 2026
Reich Kristian
Chief Scientific Officer
SELL$877.9K
Jul 15, 2026
Reich Kristian
Chief Scientific Officer
SELL$322.3K
Jul 10, 2026
Santos da Silva Jorge
Chief Executive Officer
SELL$1.4M
Jul 9, 2026
Santos da Silva Jorge
Chief Executive Officer
SELL$679.1K
Jul 1, 2026
Santos da Silva Jorge
Chief Executive Officer
SELL$956.9K

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data — subscribers only
Next Q🔒 Fresh data — subscribers only
Current FY🔒 Fresh data — subscribers only
Next FY🔒 Fresh data — subscribers only

Short side

FINRA· Sep 30, 2026
8,048,665
shares short
-10.1%
vs prior settlement
4.2
days to cover
≈9.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Clinical trial readout
🔒 Fresh data — subscribers only
Aug 11, 2026 SEC
Six institutional buyers accumulated $1.4M in MLTX during Q2 2026, led by State Street (+$644K) and Nuveen (+$328K)…
INST-CLUSTER — Impact 5/10
Aug 10, 2026 SEC
MoonLake announced positive topline Phase 3 IZAR-1 results for sonelokimab in psoriatic arthritis, meeting all…
8-K — Impact 7/10
Aug 10, 2026 SEC
MoonLake reported Q2 2026 financials alongside positive Phase 3 IZAR-1 topline results for sonelokimab in psoriatic…
PRESS-RELEASE — Impact 7/10
Jul 27, 2026 Insider
Reich Kristian sold 1,100 shares
Chief Scientific Officer @ $20.00 ($22.0K)
Jul 22, 2026 Insider
Reich Kristian sold 2,448 shares
Chief Scientific Officer @ $20.00 ($49.0K)
Jul 21, 2026 Insider
Reich Kristian sold 50,000 shares
Chief Scientific Officer @ $20.02 ($1.0M)
Jun 30, 2026 Inst.
D. E. Shaw & — ADD
3,365,507 shares ($65.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
🔒 Fresh data — subscribers only
Recent
Oct 26, 2026
Trial readout
🔒 Fresh data — subscribers only
Oct 19, 2026
Trial readout
T-90d Trial Readout: Sonelokimab (Phase 3)
Trial: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response Sponsor: MoonLake Immunotherapeutics…
Oct 12, 2026
Trial readout
T-90d Trial Readout: Sonelokimab (Phase 3)
Trial: Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response Sponsor: MoonLake Immunotherapeutics…
Oct 9, 2026
Clinical Trial
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Sep 15, 2026
Short interest
Short Interest: MLTX up 25% to 8.9M shares
Settlement 2026-09-15 | Days to cover: 6.07 | ≈10.51% of shares outstanding (est.)

SecBot reports

9 filings · 4 press releases · 4 bullish · 4 bearish · 1 neutral
All MLTX filing & press-release reports (13)